GENMAB A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,100 MXN | +3.92% |
|
-.--% | -4.52% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 19.81B 2.86B 52.47B 225B | Sales 2025 * | 23.61B 3.41B 62.55B 268B | Capitalization | 123B 17.83B 327B 1,400B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.67B 675M 12.38B 52.98B | Net income 2025 * | 6.54B 944M 17.32B 74.13B | EV / Sales 2024 * | 4.93 x |
| Net cash position 2024 * | 25.89B 3.74B 68.58B 294B | Net cash position 2025 * | 32.22B 4.65B 85.34B 365B | EV / Sales 2025 * | 3.87 x |
| P/E ratio 2024 * |
28.3
x | P/E ratio 2025 * |
20.6
x | Employees | 2,286 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 day | +3.92% | ||
| 3 months | +3.92% | ||
| 6 months | -4.26% | ||
| Current year | -4.52% |
Current year
4 907.84
5 100.00
1 year
4 907.845 375.45
3 years
4 907.849 759.80
5 years
4 907.849 759.80
10 years
4 907.849 759.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/12/98 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 31/12/06 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 22/03/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 31/12/16 |
| Director/Board Member | 73 | 31/10/03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 31/12/15 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,922
DKK
Average target price
2,464
DKK
Spread / Average Target
+28.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.77% | 125B | |
| +14.05% | 108B | |
| -7.16% | 23.64B | |
| +2.07% | 22.39B | |
| -41.74% | 16.43B | |
| -13.47% | 16.34B | |
| +2.23% | 13.56B | |
| +27.13% | 11.59B | |
| +93.29% | 9.66B |
- Stock Market
- Equities
- GMAB Stock
- GMAB N Stock
